Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
41128349 (PubMed )
Supplement: CAS-117-156-s003.xlsx › Sheet1
Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases.
Park SS et al.
Annals of Laboratory Medicine, 2025
40017228 (PubMed )
Supplement: alm-45-3-279-supple2.xlsx › Table_S3
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
37950065 (PubMed )
Supplement: 42003_2023_5475_MOESM2_ESM.pdf
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.
Omura T et al.
Cancers, 2022
35626060 (PubMed )
Supplement: cancers-14-02454-s001.zip › cancers-1674301-SI.xlsx › VUS
Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.
Aoyagi Y et al.
Plos One, 2022
35358259 (PubMed )
Supplement: pone.0266112.s001.xlsx › Patients
High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer.
Lee SE et al.
International Journal of Molecular Sciences, 2021
34074070 (PubMed )
Supplement: ijms-22-05561-s001.zip › ijms-1205781-supplementary.xlsx › Table_S1
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y et al.
Cancer Research and Treatment, 2021
Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia.
Kim B et al.
Scientific Reports, 2020
32868804 (PubMed )
Supplement: 41598_2020_71386_MOESM1_ESM.pdf
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.
Jiang J et al.
Journal of Personalized Medicine, 2018
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J et al.
Genome Medicine, 2018
29544535 (PubMed )
Supplement: 13073_2018_529_MOESM5_ESM.pdf
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI et al.
Leukemia, 2018
Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.
Martinez GS et al.
Clinical Cancer Drugs, 2016
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC et al.
Cancer Discovery, 2012
Array-based genomic resequencing of human leukemia.
Yamashita Y et al.
Oncogene, 2010
Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T et al.
British Journal of Haematology, 2008
Select a paper to view details